94
K. Igarashi and H. Ooshima
physical properties, the tubular flow type is more advantageous than the stirred tank
type which a residence time distribution. However, since the tubular type crystallizer
is not sufficiently stirred, a very long apparatus must be manufactured. Therefore,
the continuous oscillated baffled crystallizer (COBC), in which the tube is separated
into multiple compartments, is attracting attention. This section introduced a device
for obtaining large crystals and a small crystallizer for obtaining small crystals. In
the future, more sophisticated crystallizers will be developed.
References
1. Haleblia, J., Mccrone, W.: Pharmaceutical applications of polymorphism. J. Pharm. Sci. 58,
911 (1969)
2. Haleblian, J.K.: Characterization of habits and crystalline modification of solids and their
pharmaceutical applications. J. Pharm. Sci. 64, 1269–1288 (1975)
3. Brittain, H.G.: Polymorphism in Pharmaceutical Solids, 2nd edn. Informa Healthcare (2009)
4. Aguiar, A.J., Krc, J., Kinkel, A.W., Samyn, J.C.: Effect of polymorphism on absorption of
chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci. 56, 847 (1967)
5. Ooshima, H., Igarashi, K., Sasaki, Y., Azuma, M., Noda, H.: Production of large crystals of
glycine with a narrow size distribution using WWDJ-batch crystallizer. Chem. Eng. Trans. 1,
981–986 (2002)
6. Noda, H., Yamaji, H., Kuratani, N., Mukaida, T., Ohuchi, M.: Challenge to a precess revolution.
Wall Wetter. Kagaku Kougaku 63, 295–296 (1999)
7. Igarashi, K., Yamanaka, Y., Azuma, M., Ooshima, H.: Control of crystal size distribution using
a mL-scale continuous crystallizer equipped with a high speed agitator. J. Chem. Eng. Jpn. 45,
28–33 (2012)
8. Bittner, B., Mountfield, R.J.: Intravenous administration of poorly soluble new drug entities
in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.
Curr. Opin. Drug Discov. Devel. 5, 59–71 (2002)
9. Kakran, M., Sahoo, N.G., Li, L., Judeh, Z., Wang, Y., Chong, K., Loh, L.: Fabrication of drug
nanoparticles by evaporative precipitation of nanosuspension. Int. J. Pharm. 383, 285–292
(2010)
10. Lechuga-Ballesteros, D., & Rodríguez-Hornedo, N. (1995). Effects of molecular structure and growth kinetics on the morphology of l-alanine crystals. International Journal of
Pharmaceutics, 115(2), 151–160.
K. Igarashi and H. Ooshima
physical properties, the tubular flow type is more advantageous than the stirred tank
type which a residence time distribution. However, since the tubular type crystallizer
is not sufficiently stirred, a very long apparatus must be manufactured. Therefore,
the continuous oscillated baffled crystallizer (COBC), in which the tube is separated
into multiple compartments, is attracting attention. This section introduced a device
for obtaining large crystals and a small crystallizer for obtaining small crystals. In
the future, more sophisticated crystallizers will be developed.
References
1. Haleblia, J., Mccrone, W.: Pharmaceutical applications of polymorphism. J. Pharm. Sci. 58,
911 (1969)
2. Haleblian, J.K.: Characterization of habits and crystalline modification of solids and their
pharmaceutical applications. J. Pharm. Sci. 64, 1269–1288 (1975)
3. Brittain, H.G.: Polymorphism in Pharmaceutical Solids, 2nd edn. Informa Healthcare (2009)
4. Aguiar, A.J., Krc, J., Kinkel, A.W., Samyn, J.C.: Effect of polymorphism on absorption of
chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci. 56, 847 (1967)
5. Ooshima, H., Igarashi, K., Sasaki, Y., Azuma, M., Noda, H.: Production of large crystals of
glycine with a narrow size distribution using WWDJ-batch crystallizer. Chem. Eng. Trans. 1,
981–986 (2002)
6. Noda, H., Yamaji, H., Kuratani, N., Mukaida, T., Ohuchi, M.: Challenge to a precess revolution.
Wall Wetter. Kagaku Kougaku 63, 295–296 (1999)
7. Igarashi, K., Yamanaka, Y., Azuma, M., Ooshima, H.: Control of crystal size distribution using
a mL-scale continuous crystallizer equipped with a high speed agitator. J. Chem. Eng. Jpn. 45,
28–33 (2012)
8. Bittner, B., Mountfield, R.J.: Intravenous administration of poorly soluble new drug entities
in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.
Curr. Opin. Drug Discov. Devel. 5, 59–71 (2002)
9. Kakran, M., Sahoo, N.G., Li, L., Judeh, Z., Wang, Y., Chong, K., Loh, L.: Fabrication of drug
nanoparticles by evaporative precipitation of nanosuspension. Int. J. Pharm. 383, 285–292
(2010)
10. Lechuga-Ballesteros, D., & Rodríguez-Hornedo, N. (1995). Effects of molecular structure and growth kinetics on the morphology of l-alanine crystals. International Journal of
Pharmaceutics, 115(2), 151–160.